Literature DB >> 21095268

"Do GRACE (Global Registry of Acute Coronary events) risk scores still maintain their performance for predicting mortality in the era of contemporary management of acute coronary syndromes?".

Emad Abu-Assi1, Ignacio Ferreira-González, Aida Ribera, Josep R Marsal, Purificación Cascant, Magda Heras, Héctor Bueno, Pedro L Sánchez, Fernando Arós, Jaume Marrugat, David García-Dorado, Carlos Peña-Gil, Jose R González-Juanatey, Gaietà Permanyer-Miralda.   

Abstract

BACKGROUND: Although the GRACE risk scores (RS) are the preferred scoring system for risk stratification in acute coronary syndromes (ACS), little is known whether these RS still maintain their performance in the current era. We aimed to investigate this issue in a contemporary population with ACS.
METHODS: The study population composed of patients enrolled in the MASCARA national registry. The GRACE RS were calculated for each patient. Discrimination and calibration were evaluated with the C statistic and the Hosmer-Lemeshow test, in the whole population and according to the type of ACS, risk strata, and whether the patient had a history of diabetes and/or chronic renal failure. We determined if left ventricular ejection fraction (LVEF) provides incremental prognostic information above that established by the RS and whether percutaneous coronary intervention (PCI) during admission affects the performance of the score for predicting 6-month mortality.
RESULTS: The 5,985 patients constituted the validation cohort for the in-hospital mortality RS and 5,635 the validation cohort for the 6-month mortality RS. Overall, both GRACE RS demonstrated excellent discrimination (C > 0.80) and calibration (all P values in Hosmer-Lemeshow >.1). Although similar results were seen in all subgroups, the 6-month mortality RS performed significantly less well in patients undergoing PCI compared to those patients who did not (C = 0.73 vs 0.76, P < .004). Adding LVEF to the RS did not convey significant prognostic information.
CONCLUSIONS: The GRACE RS for predicting in-hospital and 6-month mortality still maintain their excellent performance in a contemporary cohort of patients with ACS. Further studies are needed to investigate the performance of the 6-month mortality GRACE score in patients undergoing in-hospital PCI. Left ventricular ejection fraction did not convey significant information over that provided by the RS.
Copyright © 2010 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21095268     DOI: 10.1016/j.ahj.2010.06.053

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  15 in total

1.  Prognostic factors of in-hospital mortality in all comers with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Authors:  Songsak Kiatchoosakun; Chaiyasith Wongwipaporn; Burabha Pussadhamma
Journal:  Heart Asia       Date:  2016-06-14

2.  Should PRECISE-DAPT be included for long-term prognostic stratification of diabetic patients with NSTEACS?

Authors:  Federico García-Rodeja Arias; Belén Álvarez Álvarez; Teba González Ferrero; Jesús Martinón Martínez; Óscar Otero García; Pablo Tasende Rey; Carla Eugenia Cacho Antonio; Charigan Abou Jokh Casas; Pilar Zuazola; Víctor Jiménez Ramos; Alberto Cordero; David Escribano; Belén Cid Álvarez; Diego Iglesias Álvarez; Rosa María Agra Bermejo; Pedro Rigueiro Veloso; José María García Acuña; Francisco Gude Sampedro; José Ramón González Juanatey
Journal:  Acta Diabetol       Date:  2021-09-13       Impact factor: 4.280

3.  Red blood cell fatty acid levels improve GRACE score prediction of 2-yr mortality in patients with myocardial infarction.

Authors:  William S Harris; Kevin F Kennedy; James H O'Keefe; John A Spertus
Journal:  Int J Cardiol       Date:  2012-10-06       Impact factor: 4.164

4.  ACHTUNG-Rule: a new and improved model for prognostic assessment in myocardial infarction.

Authors:  Sérgio Barra; Rui Providência; Luís Paiva; Francisca Caetano; Inês Almeida; Pedro Gomes; António Leitão Marques
Journal:  Eur Heart J Acute Cardiovasc Care       Date:  2012-12

5.  Identifying acute coronary syndrome patients approaching end-of-life.

Authors:  Stephen Fenning; Rebecca Woolcock; Kristin Haga; Javaid Iqbal; Keith A Fox; Scott A Murray; Martin A Denvir
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

6.  Is 6-month GRACE risk score a useful tool to predict stroke after an acute coronary syndrome?

Authors:  Belén Álvarez-Álvarez; Sergio Raposeiras-Roubín; Emad Abu-Assi; Cristina Cambeiro-González; Santiago Gestal-Romaní; Andrea López-López; Noelia Bouzas-Cruz; María Castiñeira-Busto; Ozoda Saidhodjayeva; Alfredo Redondo-Diéguez; Eva Pereira López; José María García-Acuña; José Ramón González-Juanatey
Journal:  Open Heart       Date:  2014-12-22

7.  "One-Time" versus Staged Multivessel Intervention in Intermediate to Very High-Risk Patients with Non-ST-Segment Elevation Acute Coronary Syndromes.

Authors:  Xiaofan Yu; Yi Li; Qiancheng Wang; Ming Liang; Kai Xu; Yaling Han
Journal:  Korean Circ J       Date:  2016-11-01       Impact factor: 3.243

8.  Predicting mortality after acute coronary syndromes in people with chronic obstructive pulmonary disease.

Authors:  Kieran J Rothnie; Liam Smeeth; Neil Pearce; Emily Herrett; Adam Timmis; Harry Hemingway; Jadwiga Wedzicha; Jennifer K Quint
Journal:  Heart       Date:  2016-05-13       Impact factor: 5.994

9.  Contemporary Risk Stratification After Myocardial Infarction in the Community: Performance of Scores and Incremental Value of Soluble Suppression of Tumorigenicity-2.

Authors:  Yariv Gerber; Susan A Weston; Maurice Enriquez-Sarano; Allan S Jaffe; Sheila M Manemann; Ruoxiang Jiang; Véronique L Roger
Journal:  J Am Heart Assoc       Date:  2017-10-20       Impact factor: 5.501

10.  Association between Variation of Troponin and Prognosis of Acute Myocardial Infarction before and after Primary Percutaneous Coronary Intervention.

Authors:  Xiaoxiao Zhao; Ying Wang; Chen Liu; Peng Zhou; Zhaoxue Sheng; Jiannan Li; Jinying Zhou; Runzhen Chen; Yi Chen; Hanjun Zhao; Hongbing Yan
Journal:  J Interv Cardiol       Date:  2020-07-25       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.